Sei Investments Co. Has $225.48 Million Stake in argenx SE (NASDAQ:ARGX)

Sei Investments Co. trimmed its position in shares of argenx SE (NASDAQ:ARGX) by 3.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 366,620 shares of the company’s stock after selling 14,075 shares during the period. Sei Investments Co. owned approximately 0.60% of argenx worth $225,475,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ARGX. Victory Capital Management Inc. grew its stake in argenx by 69.8% during the third quarter. Victory Capital Management Inc. now owns 1,562 shares of the company’s stock worth $847,000 after buying an additional 642 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of argenx in the third quarter worth about $453,000. Natixis Advisors LLC lifted its holdings in shares of argenx by 13.0% in the third quarter. Natixis Advisors LLC now owns 12,014 shares of the company’s stock worth $6,513,000 after acquiring an additional 1,379 shares during the last quarter. Advisors Asset Management Inc. lifted its holdings in shares of argenx by 15.3% in the third quarter. Advisors Asset Management Inc. now owns 927 shares of the company’s stock worth $503,000 after acquiring an additional 123 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of argenx by 28.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,459 shares of the company’s stock worth $1,875,000 after acquiring an additional 768 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently commented on ARGX. Truist Financial reissued a “buy” rating and issued a $700.00 target price (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Wedbush reissued an “outperform” rating and issued a $655.00 target price on shares of argenx in a report on Tuesday, December 3rd. William Blair reissued an “outperform” rating on shares of argenx in a report on Friday, February 28th. Guggenheim increased their target price on shares of argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “sell” rating to a “hold” rating in a report on Wednesday, March 12th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $687.00.

argenx Stock Performance

argenx stock opened at $615.02 on Friday. argenx SE has a 52-week low of $352.77 and a 52-week high of $678.21. The firm has a 50 day moving average price of $634.69 and a two-hundred day moving average price of $599.15. The firm has a market cap of $37.37 billion, a price-to-earnings ratio of -698.89 and a beta of 0.59.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities research analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.